Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): Rationale and study protocol

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1081-1087

  Keyzer, Charlotte A ^a   De Jong, Maarten A ^a   Van Breda, G Fenna ^b   Vervloet, Marc G ^b   Laverman, Gozewijn D ^c   Hemmelder, Marc ^d   Janssen, Wilbert M ^e   Heerspink, Hiddo J Lambers ^a   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ZGT Hospital   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e MARTINI HOSPITAL   (Netherlands)

Author keywords

Albuminuria; Paricalcitol; Randomized controlled trial; Sodium reduction

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; METOPROLOL; PARICALCITOL; PLACEBO; RAMIPRIL; RENIN; SODIUM; VITAMIN D RECEPTOR;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIETARY COMPLIANCE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE SPASM; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECEPTOR UPREGULATION; SAMPLE SIZE; SODIUM INTAKE; SODIUM RESTRICTION; STOMACH DISEASE; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; XEROSTOMIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); COMPLICATION; METHODOLOGY; PROCEDURES; STANDARDS;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DIET, SODIUM-RESTRICTED; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN;

EID: 84983738665     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv033     Document Type: Article

References (32)

1. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140
2. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-429
3. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945
4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863
5. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994;45:S174-S178
6. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540-1546
7. ONTARGET Investigators Yusuf S, Teo KK et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
8. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213
9. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl JMed 2013;369:1892-1903
10. Heerspink HJ, Gao P, Zeeuw D et al. The effect of ramipril and telmisartan on serumpotassiumand its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol 2014;21:299-309
11. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19:999-1007
12. Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011;343:d4366
13. Vegter S, Perna A, Postma MJ et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012;23:165-173
14. Lambers Heerspink HJ, Holtkamp FA, Parving HH et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012;82:330-337
15. Heeg JE, de Jong PE, van der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-279
16. Mirkovic K, van den Born J, Navis G et al. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets 2011;12:42-53
17. de Borst MH, Hajhosseiny R, Tamez H et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013;24:1863-1871
18. Zhang Y, Kong J, Deb DK et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010;21:966-973
19. Vaidya A, Forman JP, Hopkins PN et al. 25-Hydroxy vitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 2011;12:311-319
20. de Borst MH, Vervloet MG, terWee PM et al. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011;22:1603-1609
21. Yuan W, Pan W, Kong J et al. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclicAMPresponse element in the renin gene promoter. J Biol Chem 2007;282:29821-29830
22. Ito I, Waku T, Aoki M et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013;123:4579-4594
23. Zoccali C, Curatola G, Panuccio V et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014;64:1005-1011
24. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551
25. Arisz L, Donker AJ, Brentjens JR et al. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976;199:121-125
26. Laverman GD, Van Goor H, Henning RH et al. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int 2003;63:64-71
27. Mirkovic K, Frenay AS, van den et al. Renoprotective effects of vitamin D receptor agonist during low but not during high dietary sodium in adriamycin nephrosis [abstract]. J Am Soc Nephrol 2012;23;809A
28. de Boer IH. Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:566-572
29. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-684
30. Fishbane S, Chittineni H, Packman M et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647-652
31. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-255
32. 131I-hippuran. J Am Soc Nephrol 1996;7:567-572